Stimulation of host bone marrow stromal cells by sympathetic nerves promotes breast cancer bone metastasis in mice

PLoS Biology

Volumn 10, Issue 7, 2012, Pages 13-

  Campbell, J Preston ^a,b   Karolak, Matthew R ^a,b   Ma, Yun ^a,b   Perrien, Daniel S ^a,b,c   Masood Campbell, S Kathryn ^a,b   Penner, Niki L ^a   Munoz, Steve A ^a,b   Zijlstra, Andries ^a,b,d   Yang, Xiangli ^a,b   Sterling, Julie A ^a,b,d,e   Elefteriou, Florent ^a,b,d  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; CHEMOKINE RECEPTOR CXCR4; OSTEOCLAST DIFFERENTIATION FACTOR; PROPRANOLOL; STROMAL CELL DERIVED FACTOR 1; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ADRENERGIC STIMULATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; BONE METASTASIS; BREAST CANCER; CANCER CELL; CELL MIGRATION; CELL STIMULATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEUROENDOCRINE SYSTEM; NONHUMAN; OSTEOBLAST; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STRESS; STROMA CELL; SYMPATHETIC NERVE; ADRENERGIC SYSTEM; ANIMAL; BONE TUMOR; CELL MOTION; CYTOLOGY; DRUG EFFECT; EXPERIMENTAL NEOPLASM; FEMALE; METABOLISM; METASTASIS; PATHOLOGY; PHYSIOLOGY;

MUS;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; BONE MARROW CELLS; BONE NEOPLASMS; CELL MOVEMENT; FEMALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; OSTEOBLASTS; PROPRANOLOL; RECEPTORS, ADRENERGIC, BETA-2; SIGNAL TRANSDUCTION; STROMAL CELLS; SYMPATHETIC NERVOUS SYSTEM;

EID: 84864418995     PISSN: 15449173     EISSN: 15457885     Source Type: Journal    
DOI: 10.1371/journal.pbio.1001363     Document Type: Article

References (46)

1. Coleman R. E, Rubens R. D, (1987) The clinical course of bone metastases from breast cancer. Br J Cancer 55: 61-66.
2. Altekruse S. F. K. C, Krapcho M, Neyman N, Aminou R, Waldron W, et al. (2009) SEER cancer statistics review 1975-2007. In: National Cancer Institute. Bethesda M, editor.
3. Hortobagyi G. N, (1997) Chemotherapy of breast cancer: a historical perspective. Semin Oncol 24: S17-11-S17-14.
4. Kang Y, Siegel P. M, Shu W, Drobnjak M, Kakonen S. M, et al. (2003) A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3: 537-549.
5. Gupta G. P, Massague J, (2006) Cancer metastasis: building a framework. Cell 127: 679-695.
6. Studebaker A. W, Storci G, Werbeck J. L, Sansone P, Sasser A. K, et al. (2008) Fibroblasts isolated from common sites of breast cancer metastasis enhance cancer cell growth rates and invasiveness in an interleukin-6-dependent manner. Cancer Res 68: 9087-9095.
7. Lee Y. J, Karl D. L, Maduekwe U. N, Rothrock C, Ryeom S, et al. (2010) Differential effects of VEGFR-1 and VEGFR-2 inhibition on tumor metastases based on host organ environment. Cancer Res 70: 8357-8367.
8. Elefteriou F, (2005) Neuronal signaling and the regulation of bone remodeling. Cell Mol Life Sci 62: 2339-2349.
9. Takeda S, Elefteriou F, Levasseur R, Liu X, Zhao L, et al. (2002) Leptin regulates bone formation via the sympathetic nervous system. Cell 111: 305-317.
10. Moore R. E, Smith C. K 2nd, Bailey C. S, Voelkel E. F, Tashjian A. H Jr, (1993) Characterization of beta-adrenergic receptors on rat and human osteoblast-like cells and demonstration that beta-receptor agonists can stimulate bone resorption in organ culture. Bone Miner 23: 301-315.
11. Togari A, Arai M, Mizutani S, Mizutani S, Koshihara Y, et al. (1997) Expression of mRNAs for neuropeptide receptors and beta-adrenergic receptors in human osteoblasts and human osteogenic sarcoma cells. Neurosci Lett 233: 125-128.
12. Kellenberger S, Muller K, Richener H, Bilbe G, (1998) Formoterol and isoproterenol induce c-fos gene expression in osteoblast-like cells by activating beta2-adrenergic receptors. Bone 22: 471-478.
13. Katayama Y, Battista M, Kao W. M, Hidalgo A, Peired A. J, et al. (2006) Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow. Cell 124: 407-421.
14. Calvi L. M, (2006) Osteoblastic activation in the hematopoietic stem cell niche. Ann N Y Acad Sci 1068: 477-488.
15. Mendez-Ferrer S, Lucas D, Battista M, Frenette P. S, (2008) Haematopoietic stem cell release is regulated by circadian oscillations. Nature 452: 442-447.
16. Mendez-Ferrer S, Battista M, Frenette P. S, (2010) Cooperation of beta(2)- and beta(3)-adrenergic receptors in hematopoietic progenitor cell mobilization. Ann N Y Acad Sci 1192: 139-144.
17. Elmquist J. K, Strewler G. J, (2005) Physiology: do neural signals remodel bone? Nature 434: 447-448.
18. Elefteriou F, Ahn J. D, Takeda S, Starbuck M, Yang X, et al. (2005) Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature 434: 514-520.
19. Graham J, Ramirez A, Love S, Richards M, Burgess C, (2002) Stressful life experiences and risk of relapse of breast cancer: observational cohort study. BMJ 324: 1420.
20. Chida Y, Hamer M, Wardle J, Steptoe A, (2008) Do stress-related psychosocial factors contribute to cancer incidence and survival? Nature Clinical Practice Oncology 5: 466-475.
21. Thaker P. H, Han L. Y, Kamat A. A, Arevalo J. M, Takahashi R, et al. (2006) Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nature Medicine 12: 939-944.
22. Sloan E. K, Priceman S. J, Cox B. F, Yu S, Pimentel M. A, et al. (2010) The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Research 70: 7042-7052.
23. Guise T. A, Yin J. J, Taylor S. D, Kumagai Y, Dallas M, et al. (1996) Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 98: 1544-1549.
24. Yoneda T, Sasaki A, Dunstan C, Williams P. J, Bauss F, et al. (1997) Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. J Clin Invest 99: 2509-2517.
25. Rose A. A, Pepin F, Russo C, Abou Khalil J. E, Hallett M, et al. (2007) Osteoactivin promotes breast cancer metastasis to bone. Mol Cancer Res 5: 1001-1014.
26. Fata J. E, Kong Y. Y, Li J, Sasaki T, Irie-Sasaki J, et al. (2000) The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 103: 41-50.
27. Jones D. H, Nakashima T, Sanchez O. H, Kozieradzki I, Komarova S. V, et al. (2006) Regulation of cancer cell migration and bone metastasis by RANKL. Nature 440: 692-696.
28. Santini D, Perrone G, Roato I, Godio L, Pantano F, et al. (2011) Expression pattern of receptor activator of NFkappaB (RANK) in a series of primary solid tumors and related bone metastases. J Cell Physiol 226: 780-784.
29. Sood A. K, Bhatty R, Kamat A. A, Landen C. N, Han L, et al. (2006) Stress hormone-mediated invasion of ovarian cancer cells. Clin Cancer Res 12: 369-375.
30. Sastry K. S. R, Karpova Y, Prokopovich S, Smith A. J, Essau B, et al. (2007) Epinephrine protects cancer cells from apoptosis via activation of cAMP-dependent protein kinase and BAD phosphorylation. Journal of Biological Chemistry 282: 14094-14100.
31. Yoneda T, Williams P. J, Hiraga T, Niewolna M, Nishimura R, (2001) A bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking clone in vivo and in vitro. J Bone Miner Res 16: 1486-1495.
32. Kajimura D, Hinoi E, Ferron M, Kode A, Riley K. J, et al. (2011) Genetic determination of the cellular basis of the sympathetic regulation of bone mass accrual. J Exp Med 208: 841-851.
33. Killock D, (2011) Bone: Osteocyte RANKL in bone homeostasis: a paradigm shift? Nat Rev Rheumatol 7: 619.
34. Ma Y, Nyman J. S, Tao H, Moss H. H, Yang X, et al. (2011) beta2-Adrenergic receptor signaling in osteoblasts contributes to the catabolic effect of glucocorticoids on bone. Endocrinology 152: 1412-1422.
35. Thaker P. H, Han L. Y, Kamat A. A, Arevalo J. M, Takahashi R, et al. (2006) Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med 12: 939-944.
36. Yang E. V, Kim S. J, Donovan E. L, Chen M, Gross A. C, et al. (2009) Norepinephrine upregulates VEGF, IL-8, and IL-6 expression in human melanoma tumor cell lines: implications for stress-related enhancement of tumor progression. Brain Behav Immun 23: 267-275.
37. Yang E. V, Sood A. K, Chen M, Li Y, Eubank T. D, et al. (2006) Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells. Cancer Res 66: 10357-10364.
38. Canon J. R, Roudier M, Bryant R, Morony S, Stolina M, et al. (2008) Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin Exp Metastasis 25: 119-129.
39. Ellis G. K, Bone H. G, Chlebowski R, Paul D, Spadafora S, et al. (2008) Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 26: 4875-4882.
40. Yoneda T, (2011) [Anti-RANKL antibody for the management of bone metastasis]. Gan To Kagaku Ryoho 38: 1439-1445.
41. Zhang L, Teng Y, Zhang Y, Liu J, Xu L, et al. (2012) Receptor activator for nuclear factor kappa B expression predicts poor prognosis in breast cancer patients with bone metastasis but not in patients with visceral metastasis. J Clin Pathol 65: 36-40.
42. Powe D. G, Voss M. J, Zanker K. S, Habashy H. O, Green A. R, et al. (2010) Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget 1: 628-638.
43. Melhem-Bertrandt A, Chavez-Macgregor M, Lei X, Brown E. N, Lee R. T, et al. (2011) Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol 29: 2645-2652.
44. Barron T. I, Connolly R. M, Sharp L, Bennett K, Visvanathan K, (2011) Beta blockers and breast cancer mortality: a population- based study. J Clin Oncol 29: 2635-2644.
45. Smith M. R, Saad F, Coleman R, Shore N, Fizazi K, et al. (2012) Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 379: 39-46.
46. Pasquier E, Ciccolini J, Carre M, Giacometti S, Fanciullino R, et al. (2011) Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment. Oncotarget 2: 797-809.